GPS Wealth Strategies Group LLC reduced its stake in shares of Pfizer Inc. (NYSE: PFE – Get a rating) by 3.2% during the first quarter, Participation channel reports. The fund held 15,846 shares of the biopharmaceutical company after selling 522 shares during the quarter. GPS Wealth Strategies Group LLC’s holdings in Pfizer were worth $820,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also been buying and selling shares of the company recently. Econ Financial Services Corp acquired a new stake in shares of Pfizer during the fourth quarter worth $31,000. PYA Waltman Capital LLC acquired a new stake in Pfizer in Q4 worth approximately $31,000. Rinkey Investments acquired a new stake in Pfizer in Q4 worth approximately $32,000. Stuart Chaussee & Associates Inc. increased its stake in Pfizer by 108.3% in the 1st quarter. Stuart Chaussee & Associates Inc. now owns 625 shares of the biopharmaceutical company worth $32,000 after buying 325 more shares in the last quarter. Finally, TFO TDC LLC increased its stake in Pfizer by 126.9% in the 4th quarter. TFO TDC LLC now owns 667 shares of the biopharmaceutical company worth $37,000 after buying 373 additional shares in the last quarter. 66.50% of the shares are currently held by institutional investors and hedge funds.
In other news, please Jennifer B. Damico sold 4,000 shares of the company in a transaction that took place on Monday, May 16. The stock was sold at an average price of $50.50, for a total value of $202,000.00. Following the completion of the sale, the senior vice president now directly owns 15,064 shares of the company, valued at approximately $760,732. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available via this hyperlink. Additionally, Executive Vice President William R. Carapezzi, Jr. sold 32,908 shares of the company in a trade that took place on Thursday, May 12. The shares were sold at an average price of $50.00, for a total value of $1,645,400.00. Following the transaction, the executive vice president now owns 38,146 shares of the company, valued at approximately $1,907,300. Disclosure of this sale can be found here. Insiders sold a total of 41,126 shares of the company worth $2,075,003 in the past 90 days. 0.05% of the shares are held by insiders of the company.
A number of analysts have published reports on PFE shares. Goldman Sachs Group set a price target of $51.00 on Pfizer in a research note on Wednesday, May 25. JPMorgan Chase & Co. set a price target of $57.00 on Pfizer in a Tuesday, June 28 research note. SVB Leerink launched coverage on Pfizer in a research note on Monday, May 23. They issued a “market performance” rating and a $55.00 price target on the stock. Citigroup raised its price target on Pfizer from $46.00 to $57.00 and gave the company a “neutral” rating in a Tuesday, April 5 research note. To finish, StockNews.com upgraded Pfizer from a “buy” rating to a “strong buy” rating in a Tuesday, April 19 research note. Nine investment analysts gave the stock a hold rating, ten gave the company a buy rating and one gave the company a high buy rating. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $57.26.
PFE inventory opened at $52.31 on Monday. The company has a quick ratio of 1.13, a current ratio of 1.39 and a leverage ratio of 0.43. Pfizer Inc. has a 52-week low of $38.93 and a 52-week high of $61.71. The stock’s 50-day moving average is $50.66 and its two-hundred-day moving average is $52.03. The company has a market capitalization of $293.51 billion, a PE ratio of 12.00, a P/E/G ratio of 0.64 and a beta of 0.73.
Pfizer (NYSE: PFE – Get a rating) last released its quarterly earnings data on Tuesday, May 3. The biopharmaceutical company reported earnings per share (EPS) of $1.62 for the quarter, missing the consensus estimate of $1.66 per ($0.04). Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The company posted revenue of $25.66 billion for the quarter, versus $24.73 billion expected by analysts. In the same quarter of the previous year, the company had earned earnings per share of $0.93. Pfizer’s revenue for the quarter increased 76.8% compared to the same quarter last year. As a group, sell-side analysts expect Pfizer Inc. to post EPS of 6.63 for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6. Shareholders of record on Wednesday, June 29 will receive a dividend of $0.40 per share. The ex-date of this dividend is Thursday, July 28. This represents an annualized dividend of $1.60 and a yield of 3.06%. Pfizer’s dividend payout ratio is currently 36.70%.
Pfizer profile (Get a rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes and sells biopharmaceuticals worldwide. It offers drugs and vaccines in various therapeutic areas, including cardiovascular, metabolic and women’s health under the Premarin Family and Eliquis brands; biologics, small molecules, immunotherapies and biosimilars under the brands Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena and Braftovi; and sterile injectable and anti-infective drugs, and oral COVID-19 treatment under the brands Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga and Paxlovid.
Get news and reviews for Pfizer Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.